iX Biopharma’s S$14.7 Million Cash Balance Is Equity-Funded, With No FY2026 Dividend

iX Biopharma (SGX: 42C) ended its June 2026 financial year with S$14.74 million in group cash and cash equivalents, up from S$0.87 million a year earlier. That larger balance may catch a dividend investor’s eye. The company, however, declared or recommended no FY2026 dividend, saying it needed to conserve cash for product development and commercialisation. [S1, p. 54] [S4, p. 23]

The distinction is how that cash arrived. The audited annual report, released on 30 September 2026 after the August results announcement, shows substantial share funding alongside continued cash use by the business. It also includes a qualified audit opinion that merits a separate look. [S1, p. 49] [S1, p. 57] [S4, p. 25]

More cash, but more cash used in operations

Group revenue fell from S$7.77 million to S$6.85 million in FY2026. Gross profit improved, but the group still reported a S$7.99 million loss, compared with S$10.14 million the year before. The smaller accounting loss did not translate into stronger operating cash flow. [S1, p. 53]

Net cash used in operating activities rose from S$3.76 million to S$7.51 million. Including S$0.12 million of investing cash outflow, operations and investment together used about S$7.62 million. This is the clearest reason the year-end cash balance should not be read as cash available for a payout. [S1, p. 57]

Share placements brought in S$21.19 million and warrant exercises another S$1.91 million during the year, a combined S$23.10 million. After borrowing, repayments, lease payments and financing interest, net financing cash inflow was S$21.48 million. The resulting cash balance therefore reflects capital raised from investors much more than cash generated by operations. [S1, p. 57]

What the qualified opinion covers

The auditor’s qualification concerns parent-company receivables from subsidiaries, rather than a new adjustment to the group’s FY2026 revenue. The parent recognised a S$16.62 million loss allowance during FY2026. Because the auditor could not establish whether some of that allowance was needed in FY2025, it could not determine the possible effect on opening accumulated losses, receivables and year-to-year comparability. [S1, p. 49] [S1, p. 75]

The company said the qualification was confined to comparative figures and did not affect its 30 June 2026 balances. That is the board’s assessment; the auditor’s stated uncertainty about timing remains relevant when comparing the parent company’s figures across years. Investors should keep this parent-company issue separate from the group’s reported S$7.99 million loss. [S3, p. 1] [S1, p. 49] [S1, p. 53]

What to watch next

The group had S$5.22 million of current borrowings at 30 June 2026. One S$2.19 million borrowing was due in July; the annual report’s subsequent-events note says the company fully repaid that borrowing and interest, and the pledged security was released. The June balance sheet is therefore a dated snapshot, not a statement that this particular debt remains outstanding. [S1, p. 54] [S1, p. 82] [S1, p. 96]

For now, iX Biopharma’s answer to the dividend question is explicit: it is conserving cash. The useful next evidence is whether operating cash outflow moderates and the business begins funding more of its development and commercial activity internally. A larger cash balance alone does not establish dividend capacity. [S4, p. 23] [S1, p. 57]